Innovation1 Biotech

Tollovir Phase 2b/3 Clinical Trial Results

QCT-Based 3CL Protease Inhibitor for COVID-19 Treatment – Healthcare Professional Report.

Study Design and Methodology

Double-blind, placebo-controlled, randomized clinical trial conducted at Shaare Zadek Medical Center with weight-based dosing stratification.

Clinical Outcomes Analysis

Primary and secondary efficacy endpoints demonstrate significant clinical benefits across all measured outcomes.

Hospital Stay Duration Comparison

Tollovir demonstrates 40% reduction in hospitalization time with significant clinical and economic benefits

Clinical Impact Metrics

Reduction in Hospital Stay
%
Fewer Days (Mean Difference)
0
Median Days (Both Groups)
0

Mechanical Ventilation Requirements

73% relative risk reduction demonstrates significant prevention of disease progression to respiratory failure.
N = 11 patients
No Mechanical Ventilation
10 (90.9%)
Mechanical Ventilation
1 (9.1%)
N = 9 patients
No Mechanical Ventilation
6 (66.7%)
Mechanical Ventilation
3 (33.3%)

Statistical Analysis

Relative Risk Reduction
0 %
Absolute Risk Reduction
0 %
Number Needed to Treat
0 %

Safety Profile Analysis

Tollovir demonstrates superior safety profile with substantial reductions in severe adverse events, mortality, and serious complications compared to standard care.

Treatment-Emergent Adverse Events Profile

Comprehensive safety analysis shows consistent benefit across all adverse event categories with notable risk reductions.

Any Treatment-Emergent Adverse Event

Tollovir (N=11)
63.6%
Placebo (N=9)
78.8%
18% Lower

Serious Adverse
Events

Tollovir (N=11)
18.2%
Placebo (N=9)
33.3%
45% Lower

Severe Adverse
Events

Tollovir (N=11)
9.1%
Placebo (N=9)
33.3%
73% Lower

Resulting in Death

Tollovir (N=11)
9.1%
Placebo (N=9)
78.8%
59% Lower

Permanent Discontinuation

Tollovir (N=11)
9.1%
Placebo (N=9)
78.8%
Similar

Clinical Safety Metrics

Relative Risk Reduction
0 %
Absolute Risk Reduction
0 %
Number Needed to Treat
0 %

Is Tollovir Safe?

✓ Tollovir Shows Better Safety Profile
Patients treated with Tollovir experienced fewer serious side effects and complications compared to those receiving standard care alone.
11 patients in study
Any Side Effects
64%
Serious Problems
18%
Severe Problems
9%
Deaths
9%
9 patients in study
Any Side Effects
78%
Serious Problems
33%
Severe Problems
33%
Deaths
22%

Inflammatory Biomarker Analysis

Significant reductions in inflammatory markers (CRP ↓77%, IL-6 ↓32%) and coagulation markers (D-Dimer ↓99%) demonstrate controlled immune response and reduced thrombotic risk.

C-Reactive Protein

Systemic inflammation

3.44 mg/L
vs
3.44 mg/L
77% Reduction

Interleukin-6

Pro-inflammatory cytokine

24.6 pg/mL
vs
36.23 pg/mL
32% Reduction

D-Dimer

Fibrin degradation product

256 ng/mL
vs
29,554 ng/mL
99% Reduction

Download High-Resolution Clinical Data

Access publication-quality figures and data tables for clinical presentations and regulatory submissions.